ESG

Paris-based Enodia Therapeutics lands €20.7M to advance its AI platform that degrades disease-causing proteins at the point of synthesis, targeting new cures.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

At CES 2026, Riselink Technologies unveiled a new blueprint for the smart home, prioritizing on-device AI and local processing to enhance privacy and speed.

High Liner Foodservice launches fully cooked, sustainable seafood to solve labor woes and tap into the growing convenience store and QSR markets.

With survey fraud costing millions, Rep Data appoints a former Kantar CIO and Research Defender's founder to sharpen its tech and product focus.

With two key acquisitions, Currier Plastics expands its footprint and cleanroom capacity, signaling a major consolidation play by Sheridan Capital Partners.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

With a new EV plant in Santa Teresa, GreenPower aims for market dominance while New Mexico pushes its ambitious clean energy and economic development goals.

The investment giant's new podcast season tackles the energy trilemma, exploring AI's power thirst, the return of nuclear, and fossil fuel's role.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

BEGA's new BEGA Connect platform leverages cloud power and NB-IoT to simplify architectural lighting control, eliminating servers and subscription fees.

With most Arizonans needing addiction or mental health care not receiving it, one provider is launching a new plan to dismantle barriers and improve access.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.

The new venue near EpicCentral isn't just another opening; it's a strategic move in a competitive market, fueling local growth and redefining leisure.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

Frontier Airlines appoints decade-long veteran James Dempsey as its new CEO and raises its Q4 earnings outlook, signaling operational resilience.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.